Related Experiment Videos
Therapy options in cutaneous T-cell lymphoma
1Department of Dermatology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 434, Houston, TX 77030-4095, USA.
Expert Review of Anticancer Therapy
|July 13, 2002
Summary
New therapies are expanding cutaneous T-cell lymphoma (CTCL) treatment options. This review discusses optimal therapeutic agents for all CTCL stages, considering patient and disease characteristics for personalized care.
Area of Science:
- Oncology
- Dermatology
Background:
- Cutaneous T-cell lymphoma (CTCL) treatment is rapidly advancing with new drug approvals.
- Managing CTCL involves complex decisions due to a growing number of therapeutic options.
Purpose of the Study:
- To present and discuss optimal therapeutic agents for all clinical stages of CTCL.
- To guide treatment planning based on clinical staging, skin staging, and individual patient disease characteristics.
Main Methods:
- Review of currently available and investigational agents for CTCL treatment.
- Consideration of clinical staging (IA-IVB) and skin staging (T1-T4) in treatment selection.
Main Results:
- The evolving landscape of CTCL therapy includes bexarotene, denileukin diftitox, monoclonal antibodies, and novel chemotherapeutics.
- Treatment decisions are influenced by disease stage and individual patient factors.
Conclusions:
- Optimal CTCL management requires a tailored approach integrating staging and patient-specific disease characteristics.
- Emerging therapies offer new possibilities for treating all stages of CTCL.